Chapter 5

What the price pays for

At about $21.77, Doximity trades near 10x enterprise value to reported free cash flow — a multiple that reads as cheap for a debt-free, 89%-gross-margin franchise. The number rests on a free-cash-flow figure that adds back $121.6 million of stock-based compensation, an expense that nearly doubled in fiscal 2026 and now runs at 19% of revenue [1]. Charge that cost and the multiple moves to roughly 16x, and the price implies little more than the ~4% growth management has already guided. The margin of safety is real but sits in the balance sheet and the buyback, not in the headline multiple.

Owner FCF = reported free cash flow less stock-based compensation. GAAP P/E on FY2026; forward P/E on FY2027 consensus adjusted EPS. Sources: FY2026 10-K [2]; consensus estimates, July 2026.

Market cap uses 183.1 million Class A + Class B shares outstanding at the July 10, 2026 close of $21.77; net cash is $748.6 million with no debt. Sources: FY2026 10-K, liquidity [3]; Q4 FY2026 call [4]; share count per FY2026 10-K [5].

The company is a cash compounder with no leverage, so free cash flow is the right lens and net cash is a genuine offset to the market value (Platform and Price laid out the seven-year record). The question a value buyer has to settle is what quality of free cash flow the multiple is built on, and how much growth the price is asking to be paid for.

The stock-based compensation wedge

Doximity's reported free cash flow reached $326.5 million in fiscal 2026, up 19% year on year, because free cash flow adds back stock-based compensation as a non-cash item. That add-back is no longer small. Total stock-based compensation was $121.6 million in fiscal 2026, up from $72.4 million a year earlier and $51.1 million two years before — a rise driven mostly by research and development, where the AI-team build pushed the charge from $19.4 million to $46.2 million in a single year [6].

Subtract that cost from free cash flow and the picture changes. Post-compensation "owner" free cash flow was $204.8 million in fiscal 2026 against $200.9 million in fiscal 2025 — growth of about 2%, against the 19% the reported line shows.

Owner FCF = reported free cash flow less total stock-based compensation. Source: FY2026 10-K, cash-flow add-back and SBC schedule [7].

The same wedge explains a margin fact that the adjusted numbers hide. Adjusted EBITDA margin held at 55% in both fiscal 2025 and fiscal 2026, because adjusted EBITDA excludes stock-based compensation entirely — the $121.6 million charge is its single largest add-back, larger than depreciation, taxes and every other adjustment combined [8]. On a GAAP basis, operating income actually fell, from $227.8 million to $214.9 million, and the operating margin dropped from 39.9% to 33.3% even as revenue grew 13% [9]. Net income margin fell from 39% to 30% [10].

The gap between the two lines is mostly stock-based compensation, which adjusted EBITDA excludes. Sources: FY2026 10-K results of operations [11] and non-GAAP reconciliation [12].

That the compensation is paid in stock rather than cash does not make it free: it dilutes shareholders unless bought back. Doximity is buying it back, and then some. The company repurchased $432 million of stock in fiscal 2026, up from $116 million the year before, yet diluted share count fell only about 1%, from 201.2 million to 199.0 million [13]. A meaningful part of the buyback is running to stand still against the compensation it offsets — which is the honest way to read "we expect dilution from these new awards to be more than offset by our share repurchases," and management's own guidance that compensation rises to the low-20s percent of revenue in fiscal 2027 before trending down [14].

What the price implies

A reverse discounted-cash-flow makes the embedded expectation explicit. At an enterprise value of about $3.24 billion and a 10% discount rate, the price implies perpetual growth of roughly 0% on reported free cash flow, or about 3.5% on post-compensation owner free cash flow. In other words, the market is paying for continuation of the ~4% growth Doximity has already guided — and no cyclical recovery beyond it [15].

That framing squares the two multiples. On reported free cash flow the stock looks cheap (about 10x) because the denominator is generous; on owner free cash flow it looks fair (about 16x) for a business the market expects to grow low-single digits. Consensus lands in the same place: analysts model fiscal 2027 revenue of $670 million (about 4% growth) and adjusted earnings of $1.43 per share, putting the forward multiple on adjusted earnings near 15x, with a mean price target of $24.53 against the $21.77 price.

FY2027–FY2028 bars are consensus means (about 4% and 6% growth); FY2026 is actual. Source: consensus estimates as of July 2026; FY2026 actual per Q4 FY2026 call [16].

The valuation is not demanding on any measure — it is a low-teens-to-low-20s multiple on a highly profitable, net-cash business. What it is not is a distressed price that only makes sense if the slowdown reverses. Whichever free-cash-flow figure a buyer uses, the guided low-single-digit growth is roughly what the price already reflects. Market Trajectory argued the core market reads closer to a maturing niche than a cyclical trough; if that read is right, the stock is priced about where it should be, and the upside is optionality rather than mispricing.

Where the margin of safety sits

The scenarios below hold the model simple: they value post-compensation owner free cash flow of about $205 million under three growth-and-discount assumptions, add net cash of $748.6 million, and divide by 183.1 million shares. They are illustrative, and the result is most sensitive to the discount rate — the assumption over which a maturing-niche bear (who would demand a higher rate for AI-disruption risk) and a franchise bull most disagree.

Illustrative Gordon-growth valuations of ~$205M owner FCF plus $748.6M net cash over 183.1M shares. Source: derived from reported financials, FY2026 10-K [17].

The distribution is asymmetric, and the asymmetry is the case. Three things cushion the downside. First, net cash of $748.6 million is about $4.09 per share, roughly 19% of the price, and carries no offsetting debt [18]. Second, the $493 million left on the buyback authorization equals about 12% of the shares at today's price — and repurchases at roughly 16x owner free cash flow add per-share value in a way the fiscal 2026 program, executed partly at $45–73, did not [19]. Third, any monetization of AI Search — which management frames as a multibillion-dollar new addressable market and began selling in late April — is upside the price does not pay for [20].

The strongest fact against the read is that the bear case is not far-fetched: the same rising compensation that hollows out reported free cash flow reflects a real, ongoing AI investment cycle, and if a well-funded AI-native rival takes physician engagement and pharma budgets (Moat and Rivals), owner free cash flow could stall or fall rather than grow, and the multiple would compress rather than hold. What would settle it is observable and near-term: whether owner free cash flow — reported free cash flow less stock-based compensation — resumes growing once compensation trends back down from fiscal 2028, or whether the buyback is merely offsetting dilution while the underlying cash economics flatten. A buyer is paid to wait for that answer by a net-cash floor and an accretive buyback; a buyer is not paid for a recovery that has not yet appeared in the numbers.